Sakai N, Kodama N, Ohmori S, Sasaki K, Saito N
Laboratory of Molecular Pharmacology, Biosignal Research Center, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe, Japan.
Neurochem Int. 2000 Jun;36(7):567-79. doi: 10.1016/s0197-0186(99)00160-6.
Our previous report has revealed that PKC activation by 12-O-tetradecanoylphorbol 13-acetate (TPA) inhibited the uptake activity of serotonin transporter (SET), via an indirect mechanism unknown, but not likely via direct phosphorylation of SET by PKC (Sakai et al., 1997. J. Neurochem. 68, 2618-2624). To elucidate whether PKC can directly phosphorylate SET in vivo, FLAG-tagged SET (FLAG-SET) was expressed in COS-7 cells and the TPA-induced incorporation of (32)P into immunoprecipitated FLAG-SET was examined. PKC activation with TPA caused no phosphorylation of FLAG-SET expressed in COS-7 cells. On the other hand, morphological change associated with the disruption of filamentous actin (F-actin) was seen in TPA-treated COS-7 cells. Therefore, we studied the effects of cytochalasin D, an inhibitor of actin polymerization, on the uptake activity of the serotonin transporter (SET) to elucidate whether the actin cytoskeleton modulates the SET uptake activity. The treatment with cytochalasin D inhibited the uptake activity of both native and recombinant SET in a concentration-dependent manner. Eadie-Hofstee analysis revealed that cytochalasin D down-regulated the recombinant SET uptake activity by reducing the V(max), but not the K(m), mimicking the result observed in TPA-induced inhibition of SET activity (Sakai et al., 1997. J. Neurochem. 68, 2618-2624). The cytochalasin D-induced inhibition of SET activity was partially, but significantly, reversed by jasplakinolide, a cell permeable stabilizer of F-actin, whereas TPA-induced inhibition of SET activity was not reversed by jasplakinolide. To elucidate whether the subcellular localization of SET was changed in response to cytochalasin D or TPA, we expressed the SET fused with the green fluorescent protein (SET-GFP) in COS-7 cells and observed the subcellular distribution of SET-GFP under a confocal laser scanning fluorescent microscope. Neither cytochalasin D nor TPA markedly changed the SET-GFP cellular localization, although these drugs caused morphological change in the GFP-transfected COS-7 cells. In addition, SET activity was not altered by the treatment with either colchicine, an inhibitor of microtubule polymerization, or taxol, a stabilizer of microtubule polymerization. These results suggest that the SET uptake activity was regulated by the state of the actin cytoskeleton and that TPA exerts its inhibitory action on SET activity, in part, via disruption of F-actin and subsequent morphological change in cells.
我们之前的报告显示,12-O-十四酰佛波醇-13-乙酸酯(TPA)激活蛋白激酶C(PKC)会抑制5-羟色胺转运体(SET)的摄取活性,其机制尚不清楚,但不太可能是通过PKC直接使SET磷酸化(Sakai等人,1997年。《神经化学杂志》68卷,2618 - 2624页)。为了阐明PKC在体内是否能直接使SET磷酸化,在COS - 7细胞中表达了带有FLAG标签的SET(FLAG - SET),并检测了TPA诱导的(32)P掺入免疫沉淀的FLAG - SET中的情况。用TPA激活PKC未导致在COS - 7细胞中表达的FLAG - SET发生磷酸化。另一方面,在经TPA处理的COS - 7细胞中观察到了与丝状肌动蛋白(F - 肌动蛋白)破坏相关的形态变化。因此,我们研究了肌动蛋白聚合抑制剂细胞松弛素D对5-羟色胺转运体(SET)摄取活性的影响,以阐明肌动蛋白细胞骨架是否调节SET摄取活性。用细胞松弛素D处理以浓度依赖的方式抑制了天然和重组SET的摄取活性。伊迪 - 霍夫斯泰分析表明,细胞松弛素D通过降低V(max)而非K(m)下调重组SET的摄取活性,这与在TPA诱导的SET活性抑制中观察到的结果相似(Sakai等人,1997年。《神经化学杂志》68卷,2618 - 2624页)。F - 肌动蛋白的细胞可渗透稳定剂茉莉酸内酯部分但显著地逆转了细胞松弛素D诱导的SET活性抑制,而TPA诱导的SET活性抑制未被茉莉酸内酯逆转。为了阐明SET的亚细胞定位是否因细胞松弛素D或TPA而改变,我们在COS - 7细胞中表达了与绿色荧光蛋白融合的SET(SET - GFP),并在共聚焦激光扫描荧光显微镜下观察SET - GFP的亚细胞分布。尽管这些药物在转染了GFP的COS - 7细胞中引起了形态变化,但细胞松弛素D和TPA均未明显改变SET - GFP的细胞定位。此外,用微管聚合抑制剂秋水仙碱或微管聚合稳定剂紫杉醇处理均未改变SET活性。这些结果表明,SET摄取活性受肌动蛋白细胞骨架状态的调节,并且TPA对SET活性的抑制作用部分是通过破坏F - 肌动蛋白以及随后细胞的形态变化来实现的。